Eli Lilly & Co. said Tuesday that patients can now access 2.5- and 5-milligram single-dose vials of its weight-loss treatment ...

In November 2023, the U.S Food and Drug Administration (FDA) approved Zepbound (tirzepatide), an injectable prescription ...

(Zepbound is one of the medication's brand names.) Men, meanwhile, lost 19 percent of their body weight. This is a big move in the weight loss space. Here’s what you need to know about Zepbound.

Drugmaker Eli Lilly is lowering the prices of the two lowest doses of its weight loss drug Zepbound, but they won't be ...

Sept. 16, 2024 – Tiny bottles of the weight loss drug Zepbound have started arriving in mailboxes across the country. People who order the medicine directly from drugmaker Eli Lilly can pay much ...

The makers of Zepbound, one of the most popular new brands of weight loss injectables on the market, are offering a massive price cut — if you're willing to purchase and dose your syringes out ...

Glucagon-like peptide-1 (GLP-1) agonists such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are becoming ever more popular among diabetes and obesity care patients. Let's dig into Lilly's ...

Now, Eli Lilly is looking to lower that cost a little. The company, which makes treatments like Mounjaro and Zepbound, just announced that it has launched single-dose vials of the latter.

From the more popular options like Mounjaro or Ozempic – which is technically a diabetes medication that also helps with weight management – to emerging medications like WeGovy and Zepbound, there’s a ...

Eli Lilly pharmaceuticals has announced a significant price reduction for the lowest dose of Zepbound, one of its high demand medications approved for weight loss. The announcement came Aug. 29 ...

The annual cost-of-living adjustment (COLA) for Social Security for 2025 is projected to be the smallest since 2021 amid cooling inflation. The annual COLA, which boosts beneficiaries' monthly ...

Version 2.5 of Honkai: Star Rail brought the Trailblaze Continuance Mission from 2.4 to its end – and what an end it was. Aside from simply closing the ongoing narrative, this latest story arc ...